Provided by Tiger Fintech (Singapore) Pte. Ltd.

TELA Bio, Inc.

1.97
+0.12006.49%
Post-market: 2.030.0600+3.05%17:29 EDT
Volume:66.43K
Turnover:128.52K
Market Cap:77.92M
PE:-1.53
High:1.97
Open:1.86
Low:1.83
Close:1.85
Loading ...

TELA Bio (TELA) Receives a Buy from Lake Street

TIPRANKS
·
25 Jun

TELA Bio Inc. Announces Inducement Grant for New Senior VP Jim Hagen Under Nasdaq Rule 5635(c)(4)

Reuters
·
07 Jun

Tela Bio announces European launch of OviTex Inguinal Reinforced Tissue Matrix

TIPRANKS
·
04 Jun

TELA Bio Inc. Announces Low 1.2% Recurrence Rate in Robotic Inguinal Hernia Repair with OviTex Inguinal, Based on New Study

Reuters
·
04 Jun

TELA Bio Inc. Appoints Jeffrey Blizard as President to Propel Growth and Strengthen Leadership Team

Reuters
·
02 Jun

TELA Bio Appoints Jeffrey Blizard as President

THOMSON REUTERS
·
02 Jun

TELA Bio Inc. Conducted Annual Stockholders Meeting Virtually

Reuters
·
31 May

TELA Bio Inc. to Participate in 2025 Jefferies Global Healthcare Conference

Reuters
·
23 May

Piper Sandler Sticks to Their Hold Rating for TELA Bio (TELA)

TIPRANKS
·
20 May

TELA Bio Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
09 May

TELA Bio Q1 EPS $(0.25) Misses $(0.23) Estimate, Sales $18.52M Beat $17.36M Estimate

Benzinga
·
09 May

TELA Bio Inc. Reports Q1 2025 Revenue Growth of 12% to $18.5M, Net Loss Widens to $11.3M

Reuters
·
09 May

BRIEF-TELA Bio Q1 Revenue USD 18.52 Million Vs. IBES Estimate USD 17.4 Million

Reuters
·
09 May

TELA Bio Inc expected to post a loss of 20 cents a share - Earnings Preview

Reuters
·
07 May

Favourable Signals For TELA Bio: Numerous Insiders Acquired Stock

Simply Wall St.
·
02 May

Tela Bio announces U.S. launch of larger sizes of OviTex PRS

TIPRANKS
·
31 Mar

TELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex® PRS for Plastic and Reconstructive Surgery

GlobeNewswire
·
31 Mar

TELA Bio Full Year 2024 Earnings: Revenues Disappoint

Simply Wall St.
·
22 Mar

TELA Bio Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
22 Mar

TELA Bio Shares Drop 43% After Weak Q4 Growth, High Sales Turnover

GuruFocus
·
22 Mar